Predicta Biosciences delivers molecular diagnostics, artificial intelligence tools, and immunotherapeutic discovery services for hematological diseases. It operates a platform that uses whole-genome sequencing of bone marrow biopsies and circulating tumor cells to replace conventional assays and support high-resolution disease monitoring. The company complements genomic data with multiomic immune profiling to inform personalized therapy decisions. Its AI/ML engine mines a growing patient database to uncover novel therapeutic targets. Its focus includes diagnostics across patient disease progression and internal immunotherapy development.